AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NOVO RESOURCES CORP-CDI

0.105

+0.000

Volume:- -

Turnover:- -

Market Cap:37.24M

PE:-1.42

High:0.105

Open:0.105

Low:0.105

Close:0.105

Loading ...

Overview Company News Filings

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Novo Resources Completes Sampling Programs at New South Wales Gold Projects

MT Newswires Live

Top Midday Stories: UnitedHealth Under DOJ Investigation Over Medicare Billing Practices; Novo Nordisk Resolves Ozempic Shortage

MT Newswires Live

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

Novo Nordisk's Shortage of Ozempic, Wegovy Resolved

MT Newswires Live

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

MT Newswires Live

Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud

MT Newswires Live

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading

MT Newswires Live

European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading

MT Newswires Live

Novo Nordisk Weight-Loss Drug Found to Reduce Alcohol Cravings, Study Shows

MT Newswires Live

Novo Resources Seeks to Sell Or Find Partner for Western Australia Projects, Shares Rise 3%

MT Newswires Live

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live

Novo Resources Corp. Business Review

Sector Update: Health Care Stocks Lean Higher Pre-Bell Wednesday

MT Newswires Live

Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live

Market Chatter: Novo Nordisk Foundation Won't Step In to Replace US Aid for Health Sector

MT Newswires Live

What To Expect in the Markets This Week

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVO.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVO.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVO.AU\",,,,,undefined,":{"symbol":"NVO.AU","market":"AU","secType":"STK","nameCN":"NOVO RESOURCES CORP-CDI","latestPrice":0.105,"timestamp":1746144416113,"preClose":0.105,"halted":0,"volume":0,"delay":0,"nameEN":"NOVO RESOURCES CORP-CDI","floatShares":314709406,"shares":354630279,"eps":-0.07396521711068131,"marketStatus":"Trading","change":0,"latestTime":"05-02 12:26:03 AEST","open":0.105,"high":0.105,"low":0.105,"amount":0,"amplitude":0,"askPrice":0.11,"askSize":5010,"bidPrice":0.1,"bidSize":523571,"shortable":3,"etf":0,"ttmEps":-0.07396521711068131,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746165600000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1694268000000,"exchange":"ASX","adjPreClose":0.105,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVO.AU\",,,,,undefined,":{"symbol":"NVO.AU","floatShares":314709406,"roa":"-13.14%","roe":"-30.09%","lyrEps":-0.073965,"shares":354630279,"dividePrice":0,"high":0.105,"amplitude":0,"preClose":0.105,"low":0.105,"week52Low":0.081,"pbRate":"0.48","psRate":"13.23","week52High":0.16,"institutionHeld":0,"latestPrice":0.105,"committee":0.981044,"eps":-0.07396521711068131,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.07396521711068131,"open":0.105,"prevYearClose":0.094,"prevWeekClose":0.12,"prevMonthClose":0.115,"prevQuarterClose":0.098,"fiveDayClose":0.12,"twentyDayClose":0.099,"sixtyDayClose":0.09},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVO.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516634659","title":"AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634659","media":"Blockhead","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634659?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:04","pubTimestamp":1741014273,"startTime":"0","endTime":"0","summary":"AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/abbvie-stock-weight-loss-drug-gubra-licensing-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU1934455863.HKD","LU0708994859.HKD","LU1720051108.HKD","LU0203202063.USD","LU1868836757.USD","LU2491050154.USD","LU0553294199.USD","IE00BKVL7J92.USD","LU1496350502.SGD","BK4139","LU2237443549.SGD","LU2361044865.SGD","IE0009355771.USD","LU1244550494.USD","BK4581","VKTX","LU1974910355.USD","LU0234570918.USD","LU0122379950.USD","IE0002141913.USD","LU2106854487.HKD","IE00B42XCP33.USD","BK4599","LU1280957306.USD","LU0820561818.USD","LU1804176565.USD","LU1839511570.USD","LU1720051017.SGD","SG9999001176.SGD","BK4532","LU2324357040.USD","IE00BJJMRZ35.SGD","NVO.AU","SG9999015945.SGD","LU1035775433.USD","LU2023250504.SGD","LU2133065610.SGD","LU0094547139.USD","LU2237443465.HKD","GPCR","LU0109391861.USD","LU1917777945.USD","ABBV","LU1244550221.USD","BK4007","LU0006306889.USD","SG9999014914.USD","LU1267930730.SGD"],"gpt_icon":1},{"id":"2514375462","title":"Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375462","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375462?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:30","pubTimestamp":1740749453,"startTime":"0","endTime":"0","summary":"Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/TECH1_himshers_022825-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/TECH1_himshers_022825-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/hims-stock-hims-hers-health-semaglutide-shortage/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4534","LU1804176565.USD","IE00B1BXHZ80.USD","LU1917777945.USD","LU1974910355.USD","LU1814569148.SGD","LU0096364046.USD","LU0640476718.USD","SG9999018857.SGD","IE00BKVL7J92.USD","LU1291159041.SGD","LU0354030511.USD","HIMS","LU0058720904.USD","IE00BK4W5L77.USD","BK4516","LLY","LU1064131342.USD","SGXZ57979304.SGD","LU0203201768.USD","BK4007","LU1868837136.USD","LU0466842654.USD","LU2361045086.USD","LU0094547139.USD","SG9999015986.USD","LU0238689110.USD","LU1548497426.USD","LU0820561909.HKD","NVO.AU","LU0471298694.HKD","BK4599","IE00BZ1G4Q59.USD","LU1988902786.USD","IE00BJT1NW94.SGD","LU2461242641.AUD","SG9999014914.USD","SG9999015945.SGD","IE00BJLML261.HKD","LU2089984988.USD","LU2265009873.SGD","LU0079474960.USD","LU0320765059.SGD","LU2602419157.SGD","SG9999001176.SGD","NVO","SG9999017495.SGD","SG9999014906.USD","LU0006306889.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2514844079","title":"Novo Resources Completes Sampling Programs at New South Wales Gold Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2514844079","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514844079?lang=en_us&edition=fundamental","pubTime":"2025-02-27 14:18","pubTimestamp":1740637126,"startTime":"0","endTime":"0","summary":"Novo Resources  said geological and geochemical sampling campaigns designed to support drill programs planned in the second quarter were completed at the Tibooburra and John Bull gold projects in New South Wales, according to a Thursday Australian bourse filing.It collected 340 soil and 63 rock chip samples at the John Bull project and 962 soil and rock chip samples at the Tibooburra project.Results from the sampling campaigns are expected in mid-March.The tropical cyclone Zelia resulted in potential delays to drilling at its Balla Balla gold project and Karratha District in Western Australia and in the Egina joint venture area with De Grey Mining .The firm's shares fell 5% on market close on Thursday.Price : $0.10, Change: $-0.0050, Percent Change: -5.00%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DEG.AU","XAO.AU","BK7104","BK7506","XJO.AU","XKO.AU","NVO.AU","BK7507"],"gpt_icon":0},{"id":"2513179290","title":"Top Midday Stories: UnitedHealth Under DOJ Investigation Over Medicare Billing Practices; Novo Nordisk Resolves Ozempic Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2513179290","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513179290?lang=en_us&edition=fundamental","pubTime":"2025-02-22 00:59","pubTimestamp":1740157159,"startTime":"0","endTime":"0","summary":"All three major US stock indexes were down around midday trading on Friday as weak consumer sentiment data weighed on markets.In company news, UnitedHealth Group (UNH) is under investigation by the US","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e43a9aa5f3e30e0a0baefbda67f8306a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002270589.USD","NVO.AU","LU2552382132.HKD","LU0868494708.USD","IE00BQXX3C00.GBP","LU1267930490.SGD","HK0000320223.HKD","LU1868837300.USD","LU2491050154.USD","LU0107464264.USD","LU1868836757.USD","IE000ITXATA3.USD","NVO","MACW.SI","LU0158827781.USD","LU1674673691.USD","LU1261432733.SGD","LU0170899867.USD","IE00BN29S564.USD","LU1992135472.HKD","LU2265009873.SGD","GOOG","HIMS","GOOGL","BLUE","LU1852331112.SGD","LU1868836914.USD","IE00BKVL7J92.USD","IE00B5949003.HKD","AAPL","LU1868837136.USD","LU2420271590.USD","LU0784383803.USD","CG","CRWD","IE00B2B36J28.USD","HK0000320264.USD","LU1506573853.SGD","LU0724617625.USD","LU2106854487.HKD","LU0314104364.USD","USJW.SI","BK4555","BK4097","RIVN","LU1235294995.USD","BK4553","COIN","UNH","IE00BJJMRZ35.SGD"],"gpt_icon":1},{"id":"2513214322","title":"Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2513214322","media":"Blockhead","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513214322?lang=en_us&edition=fundamental","pubTime":"2025-02-22 00:05","pubTimestamp":1740153951,"startTime":"0","endTime":"0","summary":"HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/Stock-HimsHersHealth-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/Stock-HimsHersHealth-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/hims-stock-fda-wegovy-weight-loss-drugs-shortage/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SGXZ31699556.SGD","HIMS","LLY","LU0476273544.USD","LU0965509010.AUD","LU0823414551.USD","IE00BWXC8680.SGD","SG9999014880.SGD","IE0004445239.USD","LU1061106388.HKD","LU0882574055.USD","LU2403377893.USD","SG9999015358.SGD","LU0061474705.USD","NVDS.UK","LU0081259029.USD","IE0004086264.USD","LU0345768153.USD","NVD2.UK","NVIW.SI","LU0345769631.USD","NVD","NVO.AU","NVDS","LU1935043536.SGD","LU2430703095.HKD","LU2237438978.USD","NVDD","NVD3.UK","LU2125154935.USD","3NVD.UK","IE00B5949003.HKD","NVO","2NVD.UK","NVDA","HK0000320264.USD","NVDU","IE00B775H168.HKD","LU1119994496.HKD","LU1868836914.USD","NVDY","SG9999000418.SGD","SG9999001424.SGD","SNVD.UK","LU2463028550.USD","LU2491049909.HKD","LU0965508806.USD","LU2077746001.SGD","NVDX"],"gpt_icon":1},{"id":"2513429956","title":"Novo Nordisk's Shortage of Ozempic, Wegovy Resolved","url":"https://stock-news.laohu8.com/highlight/detail?id=2513429956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513429956?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:57","pubTimestamp":1740149860,"startTime":"0","endTime":"0","summary":"Novo Nordisk  has resolved its shortage of weight-loss drugs Ozempic and Wegovy, according to a US Food and Drug Administration website update.The resolved shortage issue means other companies will no longer be legally allowed to use copies of semaglutide, which is the generic name for the drugs.Shares of Novo Nordisk were up 3.9% in recent trading following the FDA's announcement, while shares of Hims & Hers Health  were down 24%.Price: 86.79, Change: +3.05, Percent Change: +3.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE00BZ1G4Q59.USD","HIMS","BK7104","LU1093756325.SGD","BK4196","BK4599","BK4532","BK4007","LU0154236417.USD","LU1093756168.USD","NVO","NVO.AU","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2512481767","title":"European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512481767?lang=en_us&edition=fundamental","pubTime":"2025-02-20 00:19","pubTimestamp":1739981997,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving lower late Wednesday morning, declining 0.57% to 1,400.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by furniture maker Natuzzi  and internet advertising firm Criteo , which climbed 7.3% and 2.4% respectively. They were followed by biopharmaceutical company Grifols  and pharmaceutical company Novo Nordisk , which increased 1.6% and 1% respectively.The decliners from continental Europe were led by electronics conglomerate Philips  and semiconductor company Sequans Communications , which dropped 12% and 3.1% respectively. They were followed by biopharmaceutical company DBV Technologies  and biotech firm BioNTech , which lost 2.7% and 2.5% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics  and biotech firm Autolus Therapeutics , which rose 4.5% and 1.7% respectively. They were followed by utilities company National Gr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","LU0029864427.USD","GRFS","LU2298321311.HKD","LU1267930573.SGD","CRTO","DAVA","BK4532","SQNS","AKTX","NGG","IE00BFMHRM44.USD","BK4201","LU0300736492.USD","LU0084288595.USD","BK4082","PHG","LU1093756325.SGD","LU1162221912.USD","BNTX","BK4107","DBVT","LU0868494617.USD","LU1035777561.USD","BK4095","LU1880398554.USD","BK4585","CRH","LU0708994859.HKD","GB00BDT5M118.USD","LU2463526074.USD","LU2041044095.USD","NVO.AU","LU0314106906.USD","LU1039938227.USD","LU2360108059.USD","NTZ","IE00BKVL7J92.USD","PUK","DAVA.AU","SHEL","LU1291149836.SGD","AFG","TCBP","LU0300736062.USD","BK4007","AUTL","BK4117","LU1019632923.USD"],"gpt_icon":1},{"id":"2512102374","title":"Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2512102374","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512102374?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:29","pubTimestamp":1739971742,"startTime":"0","endTime":"0","summary":"Novo Nordisk  is seeking up to $830 million in damages from KBP Biosciences, alleging the Singapore-based firm engaged in fraud during the 2023 sale of ocedurenone, a drug that supposedly treated hypertension, according to an Feb. 14 court document made public this week.A Singapore court has ordered all of the assets of KBP and its founder frozen, according to the ruling.The ruling stated that the court was \"satisfied that Novo has shown that it has a good arguable case against KBP for fraud under New York law, which governs the dispute.\"Novo Nordisk bought ocedurenone for up to $1.3 billion in 2023 but announced an impairment loss of about $800 million the following year after poor clinical trial results, Bloomberg reported.Novo Nordisk and KBP Biosciences did not immediately reply to MT Newswires' request for comment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE00BZ1G4Q59.USD","BK7104","LU1093756325.SGD","BK4599","LU1093756168.USD","BK4532","BK4007","LU0154236417.USD","NVO","NVO.AU","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2512164436","title":"European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2512164436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512164436?lang=en_us&edition=fundamental","pubTime":"2025-02-19 00:03","pubTimestamp":1739894589,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were sharply higher late Tuesday morning, rising 1.18% to 1,408.93 on the S&P Europe Select ADR Index.From continental Europe, the ga","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","LU0310800965.SGD","LU0128525689.USD","DBVT","BBVA","BK1231","ASND","BK4117","LU1093756325.SGD","LU0109394709.USD","DAVA","LU1267930227.SGD","LU0540923850.HKD","AKTX","AFG","NVO.AU","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0164880469.USD","BK4107","BK1601","LU0648005311.SGD","BK1610","BK4201","BK4007","BK7104","BK4142","BK4599","BCS","00005","03143","NVO","LU0516423174.USD","SLN","VRNA","HSBA.UK","EDAP","LU0516423091.SGD","IHG","ADAP","GRFS","HSBC","HSHD.SI","BK4207","LU0084288595.USD","BK4521","GNFT","BK4585","DAVA.AU","EQNR"],"gpt_icon":1},{"id":"2511408522","title":"European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2511408522","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511408522?lang=en_us&edition=fundamental","pubTime":"2025-02-14 00:09","pubTimestamp":1739462951,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking slightly lower late Thursday morning, declining 0.04% to 1,402.70 on the S&P Europe Select ADR Index.From continental E","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRFS","BK4117","IE00BKVL7J92.USD","TCBP","BK4568","EVAX","NCNA","NVO.AU","BK4007","LU0154236417.USD","UL","BCS","LU0109394709.USD","BK4169","BK4075","LU0889565916.HKD","BK4207","NOK","DGE.UK","BK4588","UN","BK4535","BK4183","BTI.AU","BK4548","ASND","IE00BMPRXR70.SGD","SAN","ULVR.UK","BK4547","LU0689626769.HKD","BDRX","LU0320765992.SGD","SLN","DEO","BTI","LU0124676726.USD","BK4139","AMRN","AFG","LU1093756168.USD","BK7142","BK4599","BK4020","BK4551","BNTX","NVO","LU1093756325.SGD","SAN.AU","BK4592"],"gpt_icon":1},{"id":"2511070473","title":"Novo Nordisk Weight-Loss Drug Found to Reduce Alcohol Cravings, Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2511070473","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511070473?lang=en_us&edition=fundamental","pubTime":"2025-02-13 01:14","pubTimestamp":1739380472,"startTime":"0","endTime":"0","summary":"Novo Nordisk's  semaglutide, sold under the brand name Ozempic, helped mitigate alcohol cravings in adults with alcohol use disorder in a clinical trial, researchers said in findings published Wednesday in the medical journal JAMA Psychiatry.The researchers said results of the randomized trial offer preliminary prospective evidence supporting efficacy of low-dose semaglutide in reducing alcohol cravings, thus justifying further investigation in larger studies.The trial that sought to evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and cravings involved nine weeks of outpatient treatment, with 48 participants receiving small doses ranging from 0.25 milligram to 1 mg per week.Novo Nordisk did not immediately reply to MT Newswires' request for comment.Price: 81.71, Change: -2.04, Percent Change: -2.43","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU0154236417.USD","BK7104","BK4599","NVO.AU","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","BK4585","BK4532","BK4588"],"gpt_icon":1},{"id":"2509264943","title":"Novo Resources Seeks to Sell Or Find Partner for Western Australia Projects, Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264943","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509264943?lang=en_us&edition=fundamental","pubTime":"2025-02-06 08:55","pubTimestamp":1738803318,"startTime":"0","endTime":"0","summary":"Novo Resources  will seek interested parties to acquire or form a joint venture in relation to the Comet Well gold project and Purdy's North gold-copper-nickel project in Western Australia, according to a Thursday Australian bourse filing.It reported a cash balance of AU$12.1 million and investments of around AU$43.8 million as of Dec. 31, 2024.It is developing drilling programs to test the high-priority conceptual shallow and deeper targets at its projects and it plans to conduct a maiden air core drilling program at the Balla Balla gold project, also in Western Australia, in the first half of 2025.The firm's shares rose 3% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVO.AU","XAO.AU","XKO.AU","BK4168","XJO.AU","WRN","BK7104"],"gpt_icon":1},{"id":"2509230968","title":"Sector Update: Health Care Stocks Rise in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2509230968","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509230968?lang=en_us&edition=fundamental","pubTime":"2025-02-06 02:58","pubTimestamp":1738781908,"startTime":"0","endTime":"0","summary":"Health care stocks were higher Wednesday afternoon, with the NYSE Health Care Index rising 1.2% and the Health Care Select Sector SPDR Fund  up 0.9%.The iShares Biotechnology ETF  climbed 2.2%.In corporate news, Boston Scientific  reported stronger-than-expected Q4 sales amid a sharp gain in its cardiovascular segment. The stock rose 1.7%.UnitedHealth Group  shares fell 1.6% following a now-deleted post from investor Bill Ackman on X questioning the company's profitability and saying that he would short its stock, Bloomberg reported.Novo Nordisk  shares rose 5%. The company reported Q4 earnings of 6.34 Danish kroner  per share, exceeding FactSet analyst consensus of 5.96 kroner.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1506573853.SGD","BK4504","LU1720051017.SGD","LU1914381329.SGD","LU1989771016.USD","XLV","LU1064131342.USD","LU0965509010.AUD","LU0738911758.USD","LU0345769631.USD","LU0795875086.SGD","LU1989772840.SGD","LU2357305700.SGD","LU0187121727.USD","LU0048584097.USD","NVO.AU","LU0545039389.USD","NVO","BSX.AU","LU1037948897.HKD","IE0005OL40V9.USD","IE00BZ1G4Q59.USD","LU2125154935.USD","IBB","IE00B19Z3B42.SGD","LU0354030511.USD","LU0154236417.USD","LU0976567544.SGD","LU2089284900.SGD","LU0820562030.AUD","LU1791710582.SGD","LU0683600562.USD","LU0234572021.USD","LU1988902786.USD","LU2461242641.AUD","LU0114720955.EUR","LU2324357040.USD","UNH","LU2125154778.USD","LU2506952097.USD","SG9999017495.SGD","BSX","LU1551013425.SGD","LU1267930730.SGD","LU1093756168.USD","IE00BJJMRX11.SGD","LU1814569148.SGD","LU1551013342.USD","IE00B19Z8X17.USD","LU0128525929.USD"],"gpt_icon":1},{"id":"2509287750","title":"Novo Resources Corp. Business Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2509287750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509287750?lang=en_us&edition=fundamental","pubTime":"2025-02-05 23:05","pubTimestamp":1738767900,"startTime":"0","endTime":"0","summary":"Gold in soil geochemistry and main prospects of the Tabba Tabba Shear Corridor. Balla Balla Project geology showing the Sholl Shear Zone and complex folded stratigraphy. Belltopper Gold Project location map with regional gold occurrences and major structures . Location of Priority Tenements adjacent to Azure Minerals’ Andover Lithium – Nickel Project.Three new high prospectivity farm-in/JV deals in December 2024, strengthening Novo’s high-quality, Australian based exploration portfolio.Direct pegging by Novo of six new exploration licenses .The Toolunga Project is underexplored with prospectivity for precious and base metal discovery and aligns with Novo’s exploration strategy targeting > 1 Moz Au potential.De Grey Mining  has satisfied it’s $7 million minimum expenditure commitment in September 2024 and have committed to a further spend of A$18 million by June 30, 2027, to earn 50% in the Becher Project. Egina is located near De Grey’s 13.6 Moz Hemi Gold Project5.Sale of remaining 20%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-resources-corp-business-review-150500126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AC","BK4136","DEG.AU","BK7507","MHC.AU","EGC","KZR.AU","XKO.AU","BK7095","XJO.AU","AZS.AU","BK7504","BK7506","LU1861219969.SGD","BK4588","LU0505663152.USD","SXG.AU","XAO.AU","KM1.AU","PLS.AU","TG1.AU","BK4545","BK4109","LU0072463663.USD","BK4096","NVO.AU","SCM","GBZ.AU","LU2463526074.USD","NST.AU","BK4093","BK4585","MRE.AU","BK4135","SQM","IP","LU0572108347.SGD","BK7104","LU1861214812.USD"],"gpt_icon":0},{"id":"2509851281","title":"Sector Update: Health Care Stocks Lean Higher Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2509851281","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509851281?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:08","pubTimestamp":1738764487,"startTime":"0","endTime":"0","summary":"Health care stocks were leaning higher premarket Wednesday, with The Health Care Select Sector SPDR Fund  up 0.2% and the iShares Biotechnology ETF  inactive.GSK  shares were up 6.4% after the company reported Q4 earnings and sales that topped analyst estimates.Novo Nordisk  shares rose 4% after the company reported higher Q4 earnings and sales.Bio-Techne  shares were up 4.8% after the company reported higher fiscal Q2 adjusted earnings and net sales.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","NVO.AU","BK4581","GSK.UK","BK4007","LU0154236417.USD","IBB","XLV","IE00B64QTZ34.USD","IE0034390439.USD","BK4588","BK7104","BK4121","LU1829250122.USD","BK4585","IE00B19Z6F94.USD","TECH.AU","LU1093756168.USD","BK4599","GSK","BK4532","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","TECH"],"gpt_icon":1},{"id":"2509528197","title":"Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509528197","media":"Blockhead","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509528197?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:51","pubTimestamp":1738763513,"startTime":"0","endTime":"0","summary":"Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2024/01/Stock-NovoNordisk-Denmark-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/01/Stock-NovoNordisk-Denmark-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4599","BK4585","LU1093756325.SGD","BK4532","LU0154236417.USD","LU1093756168.USD","BK7104","BK4588","IE00BKVL7J92.USD","NVO.AU","BK4007","IE00BZ1G4Q59.USD","NVO"],"gpt_icon":1},{"id":"2509466683","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2509466683","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509466683?lang=en_us&edition=fundamental","pubTime":"2025-02-05 00:10","pubTimestamp":1738685450,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.50% to 1,356.26 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion Biotech , which soared 36.3%, followed by biopharmaceutical company DBV Technologies , which rose 10%. They were followed by financial services companies Banco Bilbao Vizcaya Argentaria  and Banco Santander , which were up 3.3% and 3.6%, respectively.The decliners from continental Europe were led by medical device maker EDAP TMS , which fell 1.2%, followed by consumer goods company Unilever  and pharmaceutical company Novo Nordisk , which were down 0.4% and 0.1% respectively.From the UK and Ireland, the gainers were led by Akari Therapeutics  and biopharmaceutical companies TC Biopharm , which rose 5.9% and 3.3% respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group  and Verona Pharma , which increased 2% and 1% respectively.The","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","SAN","ULVR.UK","BDRX","NCNA","BK7104","EDAP","BK4585","BK4139","BK4007","BK7142","SAN.AU","BK4132","IE00BZ1G4Q59.USD","LU1093756168.USD","TCBP","VOD","AFG","BK4117","NVO","IE00BKVL7J92.USD","BK4107","BK4505","BK4599","VRNA","MREO","BK4532","BK4521","BK4592","BK4183","AKTX","BBVA","LU1093756325.SGD","DBVT","LU0124676726.USD","NVO.AU","LU0689626769.HKD","BK4207","BK4588","EVAX","BK4082"],"gpt_icon":1},{"id":"2508144133","title":"Market Chatter: Novo Nordisk Foundation Won't Step In to Replace US Aid for Health Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144133","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508144133?lang=en_us&edition=fundamental","pubTime":"2025-02-03 23:09","pubTimestamp":1738595345,"startTime":"0","endTime":"0","summary":"Novo Nordisk  owner Novo Nordisk Foundation will not step in to support health and humanitarian organizations affected by a freeze on US international aid, and will continue to concentrate on its core non-communicable disease program, Reuters reported Monday, citing an official.The foundation will focus on funding research for treatments for heart disease, diabetes, and risk factors like obesity, the report said.Novo Nordisk Foundation did not immediately respond to a request for comment from MT Newswires.Price: 82.64, Change: -1.81, Percent Change: -2.14","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7104","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","NVO","NVO.AU","BK4599","LU1093756325.SGD","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2508630182","title":"What To Expect in the Markets This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2508630182","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508630182?lang=en_us&edition=fundamental","pubTime":"2025-02-02 18:00","pubTimestamp":1738490400,"startTime":"0","endTime":"0","summary":"Earnings from tech, media, and pharmaceutical firms could be in the spotlight this week, with Google parent Alphabet  and Amazon  set to report, along with Disney  and weight-loss drugmakers Novo Nordisk  and Eli Lilly .As the Federal Reserve watches the strength of the labor market, the January employment report is scheduled for Friday, with jobless claims and private sector payrolls also due for release this week. Several Fed officials are set to deliver remarks as well.Senior Loan Officer Opinion Survey on Bank Lending Practices . Atlanta Fed President Raphael Bostic is scheduled to deliver remarks. Palantir , Equity Residential , and Tyson Foods  are scheduled to report earnings. San Francisco Fed President Mary Daly and Atlanta Fed President Raphael Bostic are scheduled to deliver remarks. Chicago Fed President Austan Goolsbee is scheduled to deliver remarks. Novo Nordisk , Walt Disney , Qualcomm , Arm Holdings , Uber Technologies , and MicroStrategy  are scheduled to report earni","market":"nz","thumbnail":"https://www.investopedia.com/thmb/uu_OqHrFAaX-LvlHoFvt9c-gsvs=/5000x3333/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2166130918-50c04a338cd4480c94e44de0f875beca.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/uu_OqHrFAaX-LvlHoFvt9c-gsvs=/5000x3333/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2166130918-50c04a338cd4480c94e44de0f875beca.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/what-to-expect-in-the-markets-this-week-8783286","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["AMZN","ARM.AU","MRK","MSTR.AU","BK4576","COP","PEP","US5Y.BOND","US2Y.BOND","BMY","GOOGL","AMD.AU","NVO","HON","BK4533","US30Y.BOND","US3Y.BOND","GOOG","PFE.AU","AMGN","EQR","US10Y.BOND","LU0708994859.HKD","LLY","USAW.SI","US6M.BOND","CBOE","AZN","PM","SPOT","TSN.AU","US7Y.BOND","EQR.AU","NVO.AU","PLTR","TSN","US12M.BOND","USJW.SI","LU1883839398.USD","RACE","AMD","DIS","PFE"],"gpt_icon":1},{"id":"2506552588","title":"Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2506552588","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506552588?lang=en_us&edition=fundamental","pubTime":"2025-01-28 00:27","pubTimestamp":1737995257,"startTime":"0","endTime":"0","summary":"Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.The drug, known as EFX, helped reverse cirrhosis of the liver in patients with metabolic dysfunction-associated steatohepatitis .CEO Dr. Andrew Cheng said EFX has \"transformational potential\" in fighting the disease.Shares of Akero Therapeutics  doubled Monday when the pharmaceutical firm that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver disease.The company said a 96-week Phase 2b study ofthose afflicted with cirrhosis caused by metabolic dysfunction-associated steatohepatitis  and given a 50mg dosage of its drug efruxifermin  showed that 39% experienced reversal of cirrhosis with no worsening of MASH. That compares to just 15% of those given placebo.Akero noted that a subgroup of patients who were not on GLP-1 weight-loss medicines, such as Novo Nordisk's  Wegovy and Eli Lilly","market":"fut","thumbnail":"https://www.investopedia.com/thmb/bjuORyMW_ZCng1ZoL1sKqOvM4Kk=/1779x546/filters:no_upscale():max_bytes(150000):strip_icc()/Akero-logo-color-861f5338b8ed4e4d8e187cf4a1d52d62.png","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/bjuORyMW_ZCng1ZoL1sKqOvM4Kk=/1779x546/filters:no_upscale():max_bytes(150000):strip_icc()/Akero-logo-color-861f5338b8ed4e4d8e187cf4a1d52d62.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/akero-therapeutics-stock-doubles-on-liver-disease-drug-trial-results-8780840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU1551013342.USD","LU1814569148.SGD","LU2106854487.HKD","LU0820561818.USD","LLY","LU0097036916.USD","BK4585","SG9999014898.SGD","SG9999015945.SGD","BK7104","LU2237443622.USD","BK4533","LU2211815571.USD","LU2361044865.SGD","LU1548497426.USD","LU0820561909.HKD","SGXZ31699556.SGD","BK4123","SG9999014906.USD","LU1061106388.HKD","LU0456855351.SGD","LU2237443895.HKD","LU0198837287.USD","AKRO","LU1035775433.USD","LU1983299246.USD","BK4139","NVO.AU","LU2461242641.AUD","LU1868837300.USD","IE00B2B36J28.USD","LU0882574139.USD","LU1057294990.SGD","LU1712237335.SGD","SG9999015952.SGD","BK4534","LU0109391861.USD","LU1868836757.USD","LU1720051017.SGD","BK4516","LU1551013425.SGD","NVO","IE00BKVL7J92.USD","LU2324357040.USD","LU0238689110.USD","LU2491049909.HKD","EFX","LU0943347566.SGD","LU0354030438.USD","LU0289739699.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":149,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVO.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVO.AU\",market:\"AU\",,,undefined,":[]}}